Article Text

Download PDFPDF
P229 A retrospective database study of persistence and adherence in patients with asthma in the UK (UK-THIN): fluticasone furoate/vilanterol (FF/VI) versus beclometasone dipropionate/formoterol (BDP/FM)
  1. H Svedsater1,
  2. M Parimi2,
  3. Q Ann2,
  4. CM Gray2,
  5. M Nixon2,
  6. N Boxall2
  1. 1Value Evidence and Outcomes, GlaxoSmithKline, Brentford, UK
  2. 2Real World Evidence Solutions, IQVIA, London, UK

Abstract

Introduction and objectives A retrospective cohort analysis was conducted comparing persistence with, and adherence to, different inhaled corticosteroid/long-acting-β2-agonist (ICS/LABA) treatments by asthma patients. Here we report findings from patients initiating treatment with either FF/VI or BDP/FM, the latter administered either as flexible or fixed-dose.

Methods Patients in the UK with data registered in The Health Improvement Network (THIN) database, who had a first prescription (index date) for any ICS/LABA between 1 January 2013–17 January 2018 (study period) and a prior asthma diagnosis, were included if they had ≥12 months medical history prior to index date plus ≥1 post-index ICS/LABA prescription. Patients were excluded if aged <18 years or if there were records for either COPD diagnosis or previous non–study ICS/LABA treatment prior to index date. Study cohorts were matched by propensity score (1:up to 4; greedy method). Primary objective was to compare persistence of comparator ICS/LABAs up to 12 months post-index treatment (time to discontinuation* including switch). Secondary objectives were: proportion of days covered (PDC) and proportion of patients with ≥50% and ≥80% PDC at 12 months post-index; and rescue use (annualised number of short-acting bronchodilator prescriptions/patient) within 12 months after treatment initiation.

Results A total of 894 patients initiating FF/VI were matched to 3433 patients initiating BDP/FM. A higher proportion of patients persisted with FF/VI versus BDP/FM over 12 months (Kaplan-Meier analysis; figure 1). The likelihood of discontinuing treatment within 12 months after initiation was 31% lower for FF/VI than BDP/FM (index year-adjusted, hazard ratio=0.69; 95% CI 0.60–0.80; p<0.001). Mean (standard deviation) PDC was 78.2 (25.1) for FF/VI and 71.0 (26.0) for BDP/FM (p<0.0001), with median 89.2 versus 75.9 and significantly higher odds of achieving ≥50% and ≥80% PDC for FF/VI versus BDP/FM (747/893 [83.7%] vs 2600/3433 [75.7%]; odds ratio=1.50; 95% CI 1.23–1.83; p<0.001 and 526/893 [58.9%] vs 1571/3433 [45.8%]; odds ratio=1.57; 95% CI 1.35-1.83; p<0.001, respectively; per-protocol analyses). Annualised rescue use was numerically similar for FF/VI (4.6) versus BDP/FM (4.7).

Conclusion UK asthma patients initiating FF/VI were more likely to have higher persistence and better adherence to treatment than those initiating BDP/FM.

GlaxoSmithKline plc. -funded study (209967/HO-18–19688).

Abstract P229 Figure 1

Primary objective: Treatment persistence with FF/VI vs BDP/FM – time to discontinuation* at 1 year

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles